In Depth 18 Jul 2025
Hyderabad’s Genome Valley, biopharma’s scale-up hub
Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.
- Latest Posts
Podcast 18 Jul 2025
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy
This week, I talked to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation.
In Depth 17 Jul 2025
New horizons in sickle cell disease treatment: Promising therapies on the way
Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.
In Depth 16 Jul 2025
Eight rare autoimmune diseases biotechs are fighting to treat
Discover eight rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them.
News and Trends 15 Jul 2025
Serial acquirer Concentra Biosciences on a buyout spree in 2025
Concentra Biosciences is buying struggling biotechs and its portfolio has been growing rapidly in 2025. Learn about what it has been up to this past year.
Best in Biotech 14 Jul 2025
Top biotech books of all time
Here are 51 great biotech books for this summer 2025 that are bound to get you hooked. From sci-fi to the nitty-gritties of biotech, we’ve got you covered!
ADVERTISEMENT
ADVERTISEMENT
News and Trends 11 Jul 2025
XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry?
Turnstone Biologics is being acquired by royalty aggregator Xoma Royalty. Discover how royalty deals are shaping the biopharma industry.
Podcast 11 Jul 2025
How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder
This week we talk about Congenital Adrenal Hyperplasia and how OMass Therapeutics is approaching it with the company CEO, Ros Deegan.
News and Trends 10 Jul 2025
Radiopharma’s new wave: Nuclidium and Actithera raise the stakes
Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.
In Depth 9 Jul 2025
New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage?
Delve into the growing field of CIPN, the most common side effect of chemotherapy, as we are getting closer to a first approval.
In Depth 8 Jul 2025
The biggest biotech funding rounds in June 2025
The companies Insmed, Cidara Therapeutics, and Cogent Biosciences bagged the biggest biotech funding rounds overall in June 2025.
In Depth 7 Jul 2025
Biotech in Vienna: a budding life science hub
As biotech in Vienna raked in €22.7 billion in 2023, there has been a significant increase in innovation, research, and employment in recent years.
ADVERTISEMENT
